FIRST AMENDMENT TO THE LICENSE AGREEMENT (BROAD REFERENCE NO. OLC2015079)License Agreement • March 11th, 2019 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment to the License Agreement (the “Amendment”), effective as of January 16, 2018 (the “Amendment Effective Date”), is between The Broad Institute, Inc. (“Broad”) and Neon Therapeutics, Inc. (“Company”).
SECOND AMENDMENT TO LICENSE AGREEMENT (BROAD REFERENCE NO. OLC2015079)License Agreement • March 11th, 2019 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Second Amendment to License Agreement (this “Amendment”), effective as of November 14, 2018 (the “Amendment Effective Date”), is made by and between The Broad Institute, Inc., a non-profit Massachusetts corporation, with a principal office at 415 Main Street, Cambridge, MA 02142 (“Broad”), and Neon Therapeutics, Inc., a Delaware corporation with a principal office at 40 Erie Street, Suite 110, Cambridge, MA 02139 (“Company”). Company and Broad are each referred to herein as a “Party” and collectively as the “Parties.”
